Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples

Home / Articles / External Government

Photo credit: InspectIR Systems (used with permission).
Photo credit: InspectIR Systems (used with permission).

April 20, 2022 | Originally published by Food and Drug Administration on April 14, 2022

The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test that detects chemical compounds in breath samples associated with a SARS-CoV-2 infection. The test can be performed in environments where the patient specimen is both collected and analyzed, such as doctor’s offices, hospitals, and mobile testing sites, using an instrument about the size of a piece of carry-on luggage. The test is performed by a qualified, trained operator under the supervision of a health care provider licensed or authorized by state law to prescribe tests and can provide results in less than three minutes.

Focus Areas

Want to find out more about this topic?

Request a FREE Technical Inquiry!